ACADIA Pharmaceuticals Inc. (ACAD) exhibits 91.7% gross margins and 7.9% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 31.2x enterprise multiple and 4.8% implied options volatility.
Sustained 91.7% gross profitability converts into 9.8% operating margin and 7.9% ROIC, outpacing sector cost of capital.
ROIC: 7.9% // GM: 91.7%YoY revenue trajectory of +11.9% paired with 2.94% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +11.9% // FCF YLD: 2.94%Altman Z-Score of 6.26 and Piotroski F-Score of 7/9 indicate low near-term refinancing stress.
ALTMAN Z: 6.26 // F-SCORE: 7/9Trading at 9.1x trailing P/E (8.5x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 9.1x // EV/EBITDA: 31.2xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $20.76 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 36.5% net margins.
NET MARGIN: 36.5% // D/E: 0.45x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for ACAD & activate live FRED threshold breach alerts.